<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810625</url>
  </required_header>
  <id_info>
    <org_study_id>IBIO-302</org_study_id>
    <nct_id>NCT03810625</nct_id>
  </id_info>
  <brief_title>Food Effect Study of D-0502 Tablet in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Open Label, Two-Sequence, Two-Period Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of D-0502 Tablet in Postmenopausal Female Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InventisBio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InventisBio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting),
      two-period, two-sequence crossover study of postmenopausal female healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">April 17, 2019</completion_date>
  <primary_completion_date type="Actual">November 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic: area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1 through 4, Day 7 through 11</time_frame>
    <description>AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM*hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: maximum plasma drug concentration (Cmax)</measure>
    <time_frame>Day 1 through 4, Day 7 through 11</time_frame>
    <description>Cmax: maximum plasma drug concentration of D-0502; Unit: nM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Time to reach the Cmax (Tmax)</measure>
    <time_frame>Day 1 through 4, Day 7 through 11</time_frame>
    <description>Tmax: Time to reach the Cmax of D-0502; Unit: hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Apparent terminal half-life (t1/2)</measure>
    <time_frame>Day 1 through 4, Day 7 through 11</time_frame>
    <description>t1/2: apparent terminal half-life of D-0502; Unit: hr</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-0502</intervention_name>
    <description>D-0502 oral tablets</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be medically documented as healthy and acceptable at physical
             examination.

          2. Subjects must have a BMI between 18.0 and 32.0 kg/m2 and a body weight of 45 kg or
             higher.

          3. Subjects must have all laboratory parameters within the normal range or considered not
             clinically significant by the principal investigator.

          4. Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically
             significant by the principal investigator.

          5. Subjects must be female with postmenopausal status defined as meeting at least one of
             the following criteria:

               1. Have undergone a bilateral oophorectomy any time in life;

               2. Age ≥60 years, or

               3. Age &lt;60 years but have cessation of regular menses ≥12 months with follicle
                  stimulating hormone (FSH) value &gt;40 milli-international units per milliliter
                  (mIU/mL) and an estradiol value &lt;40 picograms per milliliter (pg/mL) (140
                  picomoles per liter [pmol/L]).

          6. Subjects are able to understand the study procedures and risks involved and must
             provide signed informed consent to participate in the study.

        Exclusion Criteria:

          1. Subjects with any history or clinical manifestations of significant metabolic,
             hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic,
             renal, urological or psychiatric disorders, as determined by the investigator.

          2. Subjects who have any history or suspicion of kidney stones.

          3. Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B, and/or
             Hepatitis C.

          4. Subjects who have used prescription drugs, over-the-counter drugs, or natural health
             products (including herbal remedies, homeopathic and traditional medicines,
             probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty
             acids, and protein supplements used in sports) within 14 days before Day 1 of study
             medication dosing.

          5. Subjects had undergone major surgery within 3 months prior to Day 1.

          6. Subjects who is participating in a clinical research study involving the
             administration of an investigational or marketed drug or device, or who received any
             investigational test article within 5 half-lives or 30 days prior to Day 1 study
             medication dosing.

          7. Subjects with positive urine drug screen test at screening.

          8. Subjects with any condition that, in the judgment of the investigator, would place
             him/her at undue risk, or potentially compromise the results or interpretation of the
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Daytona Beach Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

